Trending Topics

and/or

100 Trending Topics found

World-Renowned Developmental Biologist Maria Jasin Wins Shaw Prize for Life Science and Medicine

Maria Jasin, PhD, developmental biologist at Sloan Kettering Institute (SKI), was named a recipient of the Shaw Prize for Life Science and Medicine. Dr. Jasin was recognized for her contributions to the research that studies localized double strand breaks in DNA stimulate recombination in mammalian cells.

  • Tuesday, May 21, 2019

High-Impact Science and Clinical Trial Results from MSK Experts Highlighted at the AACR 2019 Annual Meeting

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact mcnamarn@mskcc.org and odonnele@mskcc.org.

  • Thursday, March 28, 2019

MSK Researchers Identify a New Method to “Genetically Cloak” Cancer-Fighting Immune Cells

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

  • Tuesday, January 29, 2019

Analyzing Spinal Fluid Could Guide Brain Tumor Diagnosis and Treatment

Doctors have had limited success developing targeted therapies for the treatment of glioblastoma and lower-grade glioma, the most common primary brain cancers in adults. Targeted therapy requires matching drugs to the genetic profile of a tumor, which can substantially change throughout the course of the disease. Keeping track of these changes is particularly challenging in people with brain tumors because collecting tumor DNA requires brain surgery. But experts from MSK have shown that utilizing the minimally invasive procedure commonly called a spinal tap may help doctors better understand a tumor’s changing genetic makeup, offering clues into such traits as tumor aggressiveness.

  • Wednesday, January 23, 2019

Targeted Therapy, Sorafenib, Shows Promise as First-Line Treatment for Previously Untreatable Rare Tumors

In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.

  • Wednesday, December 19, 2018

Memorial Sloan Kettering Breast Cancer Experts to Gather at Annual San Antonio Breast Cancer Symposium

Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.

  • Monday, December 3, 2018

Memorial Sloan Kettering Researchers at ASH Annual Meeting

The world’s most comprehensive hematology meeting of the year will take place in San Diego, California, from December 1 through 4. Memorial Sloan Kettering experts are available to comment on research and breaking news out of the meeting. Follow the meeting live on Twitter using the hashtag #ASH18. For more information and to set up interviews or access photos and video, email Rebecca Williams at  mediastaff@mskcc.org.

  • Thursday, November 29, 2018

Milestone Precision Medicine Decision: FDA Approves the First Treatment with an Initial Tumor-Agnostic Indication

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

  • Monday, November 26, 2018

Adding Meaning to Their Miles: Fred’s Team Takes the TCS New York City Marathon

More than 50,000 runners traversed 26.2 miles across five boroughs for the TCS New York City Marathon. Among them were 925 participants who ran in support of Fred’s Team. Fred’s Team is the running program for Memorial Sloan Kettering Cancer Center (MSK), which is dedicated to moving closer to a world without cancer.

  • Friday, November 9, 2018

The Biden Cancer Summit: Finding Keys to Unlock Cancer Breakthroughs

Recently, thousands of people convened in Washington, DC, and across 450 communities nationwide for the Biden Cancer Summit, to build on former Vice President Joe Biden and Jill Biden’s commitment to ending cancer as we know it.

  • Wednesday, October 31, 2018